VACCINEX, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vaccinex, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2017 to Q3 2024.
  • Vaccinex, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $76K, a 33.9% decline year-over-year.
  • Vaccinex, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $388K, a 22.7% decline year-over-year.
  • Vaccinex, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $474K, a 13% decline from 2022.
  • Vaccinex, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $545K, a 0.74% increase from 2021.
  • Vaccinex, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $541K, a 26.1% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $388K $76K -$39K -33.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $427K $112K -$14K -11.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $441K $96K -$33K -25.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $474K $104K -$28K -21.2% Oct 1, 2023 Dec 31, 2023 10-K/A 2024-04-25
Q3 2023 $502K $115K -$19K -14.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $521K $126K -$12K -8.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $533K $129K -$12K -8.51% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $545K $132K -$21K -13.7% Oct 1, 2022 Dec 31, 2022 10-K/A 2024-04-25
Q3 2022 $566K $134K -$22K -14.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $588K $138K +$10K +7.81% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $578K $141K +$37K +35.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $541K $153K +$82K +115% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $459K $156K +$65K +71.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $394K $128K -$238K -65% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $632K $104K -$100K -49% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $732K $71K -$66K -48.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $798K $91K -$46K -33.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $844K $366K +$253K +224% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $591K $204K +$144K +240% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $447K $137K +$91K +198% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 $356K $137K +$94K +219% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $262K $113K +$61K +117% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $201K $60K +$24K +66.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $177K $46K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 $43K -$146K -77.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $52K +$21K +67.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $36K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2017 $189K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $31K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.